165 related articles for article (PubMed ID: 7858269)
61. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease.
Papadopoulos EB; Carabasi MH; Castro-Malaspina H; Childs BH; Mackinnon S; Boulad F; Gillio AP; Kernan NA; Small TN; Szabolcs P; Taylor J; Yahalom J; Collins NH; Bleau SA; Black PM; Heller G; O'Reilly RJ; Young JW
Blood; 1998 Feb; 91(3):1083-90. PubMed ID: 9446672
[TBL] [Abstract][Full Text] [Related]
62. Role of total body irradiation as based on the comparison of preparation regimens for allogeneic bone marrow transplantation for acute leukemia in first complete remission.
Inoue T; Ikeda H; Yamazaki H; Tang JT; Song C; Teshima T; Murayama S; Ohtani M; Shibata H; Masaoka T
Strahlenther Onkol; 1993 Apr; 169(4):250-5. PubMed ID: 8488461
[TBL] [Abstract][Full Text] [Related]
63. Allogeneic bone marrow transplantation for leukemia with marrow grafts treated by counterflow centrifugation.
De Witte T; Schattenberg A; Preijers F; Raymakers R; Muus P; Wessels J
Bone Marrow Transplant; 1993; 12 Suppl 3():S2-6. PubMed ID: 8124252
[TBL] [Abstract][Full Text] [Related]
64. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia.
Clift RA; Buckner CD; Appelbaum FR; Schoch G; Petersen FB; Bensinger WI; Sanders J; Sullivan KM; Storb R; Singer J
J Clin Oncol; 1992 Nov; 10(11):1723-9. PubMed ID: 1403055
[TBL] [Abstract][Full Text] [Related]
65. Allogeneic bone marrow transplantation with matched unrelated donors for patients with hematologic malignancies using a preparative regimen of high-dose cyclophosphamide and fractionated total body irradiation.
Geller RB; Devine SM; O'Toole K; Persons L; Keller J; Mauer D; Holland HK; Dix SP; Piotti M; Redei I; Connaghan G; Heffner LT; Hillyer CD; Waller EK; Winton EF; Wingard JR
Bone Marrow Transplant; 1997 Aug; 20(3):219-25. PubMed ID: 9257890
[TBL] [Abstract][Full Text] [Related]
66. Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation.
Alyea E; Neuberg D; Mauch P; Marcus K; Freedman A; Webb I; Anderson K; Schlossman R; Fisher D; Gribben J; Ritz J; Soiffer R
Biol Blood Marrow Transplant; 2002; 8(3):139-44. PubMed ID: 11939603
[TBL] [Abstract][Full Text] [Related]
67. Allogeneic bone marrow transplantation from partially mismatched related donors as therapy for primary induction failure acute myeloid leukemia.
Chiang KY; Van Rhee F; Godder K; Bridges K; Adams S; Mehta J; Henslee-Downey PJ
Bone Marrow Transplant; 2001 Mar; 27(5):507-10. PubMed ID: 11313684
[TBL] [Abstract][Full Text] [Related]
68. New conditioning regimens for high risk marrow transplants.
Jones RJ; Santos GW
Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():15-7. PubMed ID: 2627618
[TBL] [Abstract][Full Text] [Related]
69. Allogeneic bone marrow transplantation improves the outcome of de novo AML with trilineage dysplasia (AML-TLD).
Taguchi J; Miyazaki Y; Yoshida S; Fukushima T; Moriuchi Y; Jinnai I; Matsuo T; Kuriyama K; Tomonaga M
Leukemia; 2000 Nov; 14(11):1861-6. PubMed ID: 11069020
[TBL] [Abstract][Full Text] [Related]
70. Chemotherapy for induction of remission of childhood acute myeloid leukemia followed by marrow transplantation or multiagent chemotherapy: a report from the Childrens Cancer Group.
Nesbit ME; Buckley JD; Feig SA; Anderson JR; Lampkin B; Bernstein ID; Kim TH; Piomelli S; Kersey JH; Coccia PF
J Clin Oncol; 1994 Jan; 12(1):127-35. PubMed ID: 8270968
[TBL] [Abstract][Full Text] [Related]
71. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
72. Early toxicity of intensified conditioning with etoposide combined with total body irradiation/cyclophosphamide or busulfan/cyclophosphamide in children undergoing autologous or allogeneic bone marrow transplantation.
Horstmann M; Kroschke G; Stockschläder M; Betker R; Krüger W; Erttmann R; Kabisch H; Zander A
Pediatr Hematol Oncol; 1996; 13(1):45-53. PubMed ID: 8718502
[TBL] [Abstract][Full Text] [Related]
73. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen.
Linker CA; Ries CA; Damon LE; Rugo HS; Wolf JL
Blood; 1993 Jan; 81(2):311-8. PubMed ID: 8422457
[TBL] [Abstract][Full Text] [Related]
74. Childhood acute myeloid leukemia: outcome in a single center using chemotherapy and consolidation with busulfan/cyclophosphamide for bone marrow transplantation.
Shaw PJ; Bergin ME; Burgess MA; Dalla Pozza L; Kellie SJ; Rowell G; Stevens MM; Webster BH; Bradstock KF
J Clin Oncol; 1994 Oct; 12(10):2138-45. PubMed ID: 7931485
[TBL] [Abstract][Full Text] [Related]
75. Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. Catalan Group for Bone Marrow Transplantation.
Sierra J; Brunet S; Grañena A; Olivé T; Bueno J; Ribera JM; Petit J; Besses C; Llorente A; Guardia R; Macía J; Rovira M; Badell I; Vela E; Díaz de Heredia C; Vivancos P; Carreras E; Feliu E; Montserrat E; Julía A; Cubells J; Rozman C; Domingo A; Ortega JJ
J Clin Oncol; 1996 Apr; 14(4):1353-63. PubMed ID: 8648394
[TBL] [Abstract][Full Text] [Related]
76. Growth in children after bone marrow transplantation for acute leukemia.
Huma Z; Boulad F; Black P; Heller G; Sklar C
Blood; 1995 Jul; 86(2):819-24. PubMed ID: 7606013
[TBL] [Abstract][Full Text] [Related]
77. Autologous bone marrow transplantation for first remission acute myeloblastic leukemia in patients older than 50 years: a retrospective analysis of the European Bone Marrow Transplant Group.
Cahn JY; Labopin M; Mandelli F; Goldstone AH; Eberhardt K; Reiffers J; Ferrant A; Franklin I; Hervé P; Gratwohl A
Blood; 1995 Jan; 85(2):575-9. PubMed ID: 7812012
[TBL] [Abstract][Full Text] [Related]
78. Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia. A study of the European Cooperative Group for Blood and Marrow Transplantation (EBMT).
Gorin NC; Labopin M; Fouillard L; Meloni G; Frassoni F; Iriondo A; Brunet Mauri S; Goldstone AH; Harousseau JL; Reiffers J; Esperou-Bourdeau H; Gluckman E
Bone Marrow Transplant; 1996 Jul; 18(1):111-7. PubMed ID: 8832003
[TBL] [Abstract][Full Text] [Related]
79. Long-term outcome of postremission chemotherapy for adults with acute myeloid leukemia using different dose-intensities.
Jehn U
Leuk Lymphoma; 1994 Sep; 15(1-2):99-112. PubMed ID: 7532060
[TBL] [Abstract][Full Text] [Related]
80. Significance of Granulocyte Colony-Stimulating Factor-Combined High-Dose Cytarabine, Cyclophosphamide, and Total Body Irradiation in Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignant Neoplasms.
Nakamura Y; Tanaka Y; Tanaka M; Yamamoto K; Matsuguma M; Kajimura Y; Tokunaga Y; Yujiri T; Tanizawa Y
Transplant Proc; 2019 Apr; 51(3):896-900. PubMed ID: 30979482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
